Aerovate Therapeutics EPS - Earnings per Share 2020-2024 | JBIO
Aerovate Therapeutics eps - earnings per share from 2020 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Aerovate Therapeutics Annual EPS |
| 2024 |
$-2.44 |
| 2023 |
$-2.87 |
| 2022 |
$-2.10 |
| 2021 |
$-1.87 |
| 2020 |
$-40.31 |
| 2019 |
$-13.79 |
| Aerovate Therapeutics Quarterly EPS |
| 2024-12-31 |
$-0.19 |
| 2024-09-30 |
$-0.56 |
| 2024-06-30 |
$-0.86 |
| 2024-03-31 |
$-0.83 |
| 2023-12-31 |
$-0.73 |
| 2023-09-30 |
$-0.71 |
| 2023-06-30 |
$-0.76 |
| 2023-03-31 |
$-0.67 |
| 2022-12-31 |
$-0.60 |
| 2022-09-30 |
$-0.56 |
| 2022-06-30 |
$-0.49 |
| 2022-03-31 |
$-0.45 |
| 2021-12-31 |
$33.68 |
| 2021-09-30 |
$-0.26 |
| 2021-06-30 |
$-23.80 |
| 2021-03-31 |
$-11.49 |
| 2020-12-31 |
$-15.11 |
| 2020-09-30 |
$-10.13 |
| 2020-06-30 |
$-9.12 |
| 2020-03-31 |
$-5.95 |
| 2019-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.008B |
$0.000B |
|
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
|
